No Data
Hong Kong stocks unusual movement | Hua Hao Zhongtian Pharmaceuticals-B (02563) rose nearly 14% on the second day of listing. The core product You Tidelong Injection has been included in medical insurance.
Huahao Zhongtian Pharmaceutical - B (02563) rose nearly 14% on the second day of listing, as of the time of publication, up 7.21%, trading at 22.3 Hong Kong dollars, with a turnover of 12.9399 million Hong Kong dollars.
After boosting the stock price by 30% with the "routine callback", what supports the market cap of nearly 8 billion Hong Kong dollars for Huahao Zhongtian Pharmaceutical - B (02563)?
In short, the weak profit performance, relying solely on a single core product for research and development, creates a certain degree of uncertainty in the future performance of Huahao Zhongtian Pharmaceutical. In addition, with the poor performance of the synthetic biology sector globally on the secondary market, Huahao Zhongtian Pharmaceutical needs to continuously optimize its fundamentals if it wants to prove itself in the Hong Kong stock market, while strengthening innovation and further enhancing its hematopoietic capacity.
Hong Kong Stocks Extend Losses; Beijing Biostar Pharmaceuticals Soars 30% in Debut
Hong Kong stock market anomaly | The new stock Huahao Zhongtian Medicine-B (02563) rose by more than 60%. The company is committed to developing innovative drugs for tumors. Urodelone injection is the core product.
The new stock of Huahao Zhongtian Pharmaceutical-B (02563) debuted with a high opening and continued to rise. Intraday gain expanded by over 60%. As of the press time, it increased by 52.81% to 24.45 Hong Kong dollars, with a turnover of 48.9312 million Hong Kong dollars.
Hua Hao Zhongtian Pharmaceutical - B (2563.HK): Driven by synthetic biology technology, it is creating a new force of innovative drugs for cancer.
The Federal Reserve announced a 50 basis points rate cut on September 18, 2024, marking a shift from a tightening cycle to an easing cycle in monetary policy. Meanwhile, the Chinese government also implemented a series of fiscal and monetary policies to boost domestic demand, including issuing ultra-long special national bonds and reducing reserve requirements and interest rates by the central bank. The implementation of these policies released liquidity, providing support to the capital markets. Against this backdrop, the healthcare sector in the Hong Kong stock market was boosted and performed well in this round of rebound. In the third quarter of 2024, the fund holdings in the healthcare industry continued to rise, with the size of healthcare funds reaching 314.1 billion yuan, an increase of 15% compared to the previous period.
On the first day of new shares | Huahao Zhongtian Medicine-B (02563) listed for the first time, opening 34.38% higher in the morning.
Huahao Zhongtian Pharmaceutical-B (02563) is listed for the first time. The announcement shows that the pricing per share is 16 Hong Kong dollars, with a total issuance of 14.588 million shares, and 200 shares per lot. The net proceeds will be approximately 0.19589 billion Hong Kong dollars. As of the time of writing, it has risen by 34.38% to 21.5 Hong Kong dollars, with a turnover of 22.4505 million Hong Kong dollars.
No Data
No Data